Gc Cell Signs Mou With Kalbe Affiliate

By Author: Ben Gross
Total Articles: 460
Comment this article

GC Cell, a leading company in cell and gene therapy, is excited to announce the signing of an MOU for a strategic partnership with Bifarma, a key player in stem cell therapy in Indonesia. Bifarma, a subsidiary of PT Kalbe Farma Tbk, Southeast Asia's top pharmaceutical company, has strong capabilities in R&D, GMP-compliant manufacturing, and commercializing cell therapies.

This partnership is a significant move towards entering the Indonesian market and expanding into the innovative cell therapy sector. It will help introduce 'Immuncell-LC', an approved autologous T-cell therapy for liver cancer surgery in Korea, to Indonesia. The MOU also involves collaboration on technology transfer and developing NK cell therapy pipelines.

GC Cell recently revealed its Blueprint 2.0 strategy, focusing on future growth drivers. A key part of this strategy is the global launch of its cell therapy products, including Immuncell-LC, Korea's pioneering cell therapy, and establishing NK cell therapy pipelines in the Asia-Pacific region.

Indonesia, with its large population and rapid growth, along with the rise of universal ...
... healthcare, offers a promising market for autologous cell therapies. These therapies are becoming more accessible through medical procedures supported by strong clinical data, similar to those in Japan. Through the partnership with Bifarma and leveraging the Kalbe Group's local infrastructure, GC Cell looks forward to launching Immuncell-LC in Indonesia swiftly.

More Information : https://www.techdogs.com/tech-news/pr-newswire/gc-cell-signs-an-mou-with-pt-bifarma-adiluhung-an-affiliate-of-kalbe-group